112
Views
2
CrossRef citations to date
0
Altmetric
Article Commentary

Professional Challenges for United States Hematology/Oncology Trainees during COVID-19

ORCID Icon, ORCID Icon, , , , , , ORCID Icon & show all
Pages 539-547 | Received 09 Nov 2022, Accepted 31 Mar 2023, Published online: 11 Apr 2023
 

Abstract

COVID-19 has been devastating for patients with cancer. In this commentary, we chronicle the pandemic’s downstream impacts on United States hematology/oncology trainees in terms of professional development and career advancement. These include loss of access to clinical electives and protocol workshops, delays in research approval and execution, mentor shortages due to academic burnout, and obstacles with career transitions (most notably the post-fellowship job search). While certain silver linings from the pandemic have undoubtedly emerged, continued progress against COVID-19 will be essential to fully overcome the professional challenges it has created for the future hematology/oncology workforce.

Acknowledgments

The authors wish to acknowledge their patients during the pandemic as well as their mentors who persevered as excellent clinicians and teachers.

Author contribution

All authors contributed to manuscript conceptualization and manuscript content. RB wrote the first draft of the manuscript, and all authors provided edits and agreed upon the final version of the manuscript.

Declaration of interest

Dr. Banerjee: Consulting: BMS/Celgene, Genentech/Roche, Janssen Oncology, Sanofi Pasteur, SparkCures; Research funding: Pack Health. Dr. Kareff: Research funding: GMaP Region 3. Dr. Desai: Consulting: Sanofi. Dr. Tsang: Stock ownership, AVEO Pharmaceuticals, Poseida Therapeutics. Dr. Velazquez: Consulting: AstraZeneca; Honoraria: Curio Science, ObR Oncology, MD Outlook, CME Outfitters, MJH Life Sciences, ASCO; Travel: DAVA Oncology, BioAscend, ASCO; Stock ownership: Corbus Pharmaceuticals; Research Funding: National Institute on Aging (under award P30AG015272), National Cancer Institute (under award U54 CA242646-04S2). The remaining authors report no disclosures.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.